Intravenous infusion of prostaglandin F2alpha in the mid-luteal phase of the normal human menstrual cycle.
D000328:Adult; D001667:Binding, Competitive; D001681:Biological Assay; D001831:Body Temperature; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D003338:Corpus Luteum / Q000187:drug effects / Q000502:physiology; D004967:Estrogens / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007275:Injections, Intravenous; D007986:Luteinizing Hormone / Q000097:blood; D008598:Menstruation / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects; D011374:Progesterone / Q000097:blood; D011453:Prostaglandins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D011863:Radioimmunoassay
D006063:Chorionic Gonadotropin; D004967:Estrogens; D011453:Prostaglandins; D011374:Progesterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone